HRID1885712

反应详情

EQUATION

反应方程式

REACTANTS

反应物

结构：OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1

HCID3108

Dipyridamole

C24H40N8O4

HCID4850

Piribedil

C16H18N4O2

结构：COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O

HCID8969

Yohimbine

C21H26N2O3

结构：CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1.O=C(O)C(O)C(O)C(=O)O

HCID6419987

未命名化合物

结构：CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2

HCID178481186

未命名化合物

PRODUCTS

生成物

结构：COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC

HCID4680

Papaverine

C20H21NO4

PROCEDURE

实验过程

ifenprodil tartrate approximately 0.75 mg as an alpha1 blocker; atropine approximately 0.025 mg as an anticholinergic; yohimbine approximately 0.075 mg as an alpha2 blocker; dipyridamol approximately 0.25 mg as a phosphodiasterase inhibitor; piribedil approximately 0.225 mg as a dopaminergic; and alprostil approximately 33 μg as a prostaglandin.

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-9a9b9e7ea289493c8c96112a591cb49f
来源数据集: uspto-grants-1992_09
DOI: 10.6084/m9.figshare.5104873.v1
专利: US05145852
来源说明: uspto-grants-1992_09

反应 SMILES

C[CH:2]([N:12]1[CH2:17][CH2:16][CH:15]([CH2:18][C:19]2[CH:20]=[CH:21][CH:22]=CC=2)CC1)[CH:3](O)[C:4]1[CH:5]=[CH:6][C:7]([OH:10])=[CH:8][CH:9]=1.C(O)(C(O)=O)C(O)[C:27](O)=[O:28].CN1[C@@H]2C[C@@H:42]([O:44]C(C(C3C=CC=CC=3)CO)=O)C[C@H]1CC2.[CH3:56][O:57]C([C@@H]1[C@H]2C[C@@H]3N(C[C@@H]2CC[C@@H]1O)CCC1C2C=CC=CC=2NC3=1)=O.[CH2:82]1CCN(C2C3N=C(N(CCO)CCO)N=C(N4CCCCC4)C=3N=C(N(CCO)CCO)N=2)CC1.C1C=NC(N2CCN(CC3C=CC4OCOC=4C=3)CC2)=NC=1>>[CH3:27][O:28][C:20]1[CH:21]=[CH:22][C:15]([CH2:16][C:17]2[N:12]=[CH:2][CH:3]=[C:4]3[C:9]=2[CH:8]=[C:7]([O:10][CH3:82])[C:6]([O:57][CH3:56])=[CH:5]3)=[CH:18][C:19]=1[O:44][CH3:42]